First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants

SARS-CoV-2 and its variants have persisted in this ongoing COVID-19 pandemic. While the vaccines have greatly reduced the COVID-19 cases, hospitalizations, and death, about half of the world remain unvaccinated due to various reasons. Furthermore, the duration of the immunity gained from COVID-19 va...

Descripción completa

Detalles Bibliográficos
Autores principales: Titong, Allison, Gallolu Kankanamalage, Sachith, Dong, Jianbo, Huang, Betty, Spadoni, Nicholas, Wang, Bo, Wright, Meredith, Pham, Keegan L. J., Le, Anh Hai, Liu, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905027/
https://www.ncbi.nlm.nih.gov/pubmed/35264679
http://dx.doi.org/10.1038/s41598-022-07952-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905027/
https://www.ncbi.nlm.nih.gov/pubmed/35264679
http://dx.doi.org/10.1038/s41598-022-07952-4

Ejemplares similares